'
Total revenue from operations jumped 24.26% year-on-year to Rs 7,167.52 crore in the quarter ended 31 December 2025.
Profit before tax stood at Rs 1,522.04 crore during the quarter, up 4207% from Rs 1,071.27 crore recorded in Q3 FY25.
EBITDA stood at Rs 2,376.6 crore in Q3 FY26, registering a 68.6% growth compared with Rs 1,409.80 crore in Q3 FY25. The EBITDA margin improved 840 basis points to 33.5% in Q3 FY26 from 25.1% in Q3 FY25.
U.S. sales for Q3 FY26 rose 54% to Rs 3,113.2 crore ($350 million) from Rs 2,022.1 crore ($240 million) in Q3 FY25, accounting for 44% of the company’s global sales. During the quarter, the company received 1 ANDA approval from the U.S. FDA and launched 3 products in the U.S., taking its total generic portfolio to 149 products.
Lupin continues to be the 3rd largest pharmaceutical player in both U.S. generic market and U.S. total market by prescriptions (IQVIA Qtr. TRx Dec 2025). Lupin is the leader in 55 of its marketed g...
Pleaselogin & subscribe to view the full report.
More Reports
-
(05-Feb-2025)
Castrol India
Expects EBITDA margin of 22%-25% for CY25
-
(10-Feb-2023)
Deepak Nitrite
Plans capex of about Rs 1500 crore for FY23 and FY24
-
(09-Feb-2023)
Mayur Uniquoters
Targets revenue of Rs 1000 crore in FY24
-
(31-Jan-2023)
Tega industries
Capex plan is US$ 30-32 million for next three years
|
|